Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review

Hao, Yuxuan; Zhang, Xiaoye; Yu, Li

doi:10.3389/fonc.2022.911906

Cited by 9 publications

(9 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ICIs have demonstrated the therapeutic benefits in NSCLC. But ICIs have several side effects, such as ICI-related pneumonitis (Conroy and Naidoo, 2022;Hao et al, 2022). Altogether, nanoparticle-based ICI therapy can boost the anti-tumor immunity in lung cancer (Figure 1).…”

Section: Discussionmentioning

confidence: 99%

“…For example, one ICI ipilimumab blocks CTLA-4, pembrolizumab and nivolumab blocks PD-1, and atezolizumab, avelumab and durvalumab blocks PD-L1 (Huang and Zappasodi, 2022;Tison et al, 2022). Therefore, ICI therapy has been used in various cancer types, including lung cancer (Fang and Su, 2022;Hao et al, 2022;Mussafi et al, 2022;Punekar et al, 2022;Zulfiqar et al, 2022).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Nanoparticles overcome adaptive immune resistance and enhance immunotherapy via targeting tumor microenvironment in lung cancer

et al. 2023

View full text Add to dashboard Cite

Lung cancer is one of the common malignant cancers worldwide. Immune checkpoint inhibitor (ICI) therapy has improved survival of lung cancer patients. However, ICI therapy leads to adaptive immune resistance and displays resistance to PD-1/PD-L1 blockade in lung cancer, leading to less immune response of lung cancer patients. Tumor microenvironment (TME) is an integral tumor microenvironment, which is involved in immunotherapy resistance. Nanomedicine has been used to enhance the immunotherapy in lung cancer. In this review article, we described the association between TME and immunotherapy in lung cancer. We also highlighted the importance of TME in immunotherapy in lung cancer. Moreover, we discussed how nanoparticles are involved in regulation of TME to improve the efficacy of immunotherapy, including Nanomedicine SGT-53, AZD1080, Nanomodulator NRF2, Cisplatin nanoparticles, Au@PG, DPAICP@ME, SPIO NP@M-P, NBTXR3 nanoparticles, ARAC nanoparticles, Nano-DOX, MS NPs, Nab-paclitaxel, GNPs-hPD-L1 siRNA. Furthermore, we concluded that targeting TME by nanoparticles could be helpful to overcome resistance to PD-1/PD-L1 blockade in lung cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Nanoparticles overcome adaptive immune resistance and enhance immunotherapy via targeting tumor microenvironment in lung cancer

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Moreover, adaptive immune resistance is observed in lung cancer patients and attenuated the immunotherapeutic benefits ( Gkountakos et al, 2021 ; Gemelli et al, 2022 ). Furthermore, immunotherapy often causes side-effects, such as endocrinopathy, colitis, pneumonitis, nephritis in lung cancer patients ( Bredin and Naidoo, 2022 ; Hao et al, 2022 ).…”

Section: Introductionmentioning

confidence: 99%

Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer

Wang

Zhu²,

Yang³

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Lung cancer is the common malignant tumor with the highest mortality rate. Lung cancer patients have achieved benefits from immunotherapy, including immune checkpoint inhibitors (ICIs) therapy. Unfortunately, cancer patients acquire adaptive immune resistance, leading to poor prognosis. Tumor microenvironment (TME) has been demonstrated to play a critical role in participating in acquired adaptive immune resistance. TME is associated with molecular heterogeneity of immunotherapy efficacy in lung cancer. In this article, we discuss how immune cell types of TME are correlated with immunotherapy in lung cancer. Moreover, we describe the efficacy of immunotherapy in driven gene mutations in lung cancer, including KRAS, TP53, EGFR, ALK, ROS1, KEAP1, ZFHX3, PTCH1, PAK7, UBE3A, TNF-α, NOTCH, LRP1B, FBXW7, and STK11. We also emphasize that modulation of immune cell types of TME could be a promising strategy for improving adaptive immune resistance in lung cancer.

show abstract

“…Non-small cell lung cancer (NSCLC) accounts for >75% of all cases of lung cancer and can be further classified into 3 subtypes; that is, adenocarcinoma (AC), squamous cell carcinoma (SCC), and large cell carcinoma (2)(3)(4)(5). A number of studies have successfully applied molecular-targeted therapeutic agents and d e m o n s t r a t e d t h e i r s u p e r i o r i t y t o c o n v e n t i o n a l chemotherapy in treating NSCLC (6)(7)(8). For example, the echinoderm microtubule-associated protein like4anaplasticlymphoma kinase and epidermal growth factor receptor (EGFR) are important treatment modalities for NSCLC (9)(10)(11)(12).…”

Section: Introductionmentioning

confidence: 99%

High expression of FGFR3 predicts a better prognosis for patients with non-small cell lung cancer in a Chinese population

Lin¹,

Long²,

Chen³

et al. 2023

J Thorac Dis

View full text Add to dashboard Cite

Background This study sought to examine the expression and mutation status of fibroblast growth factor receptor 3 (FGFR3) in non-small cell lung cancer (NSCLC) tissues and explore the prognostic potential of FGFR3 in NSCLC. Methods Immunohistochemistry (IHC) was used to evaluate the FGFR3 protein expression of 116 NSCLC tissues. Sanger sequencing was used to examine the mutation status of exons 7, 10, and 15 in FGFR3. A Kaplan‑Meier survival analysis was conducted to evaluate the association between the expression level of FGFR3 and the overall survival (OS) and disease-free survival (DFS) of NSCLC patients. Univariate and multivariate Cox analyses were conducted to examine the association between the risk score and clinical features. Results FGFR3 was immunoreactive in 26 of the 86 NSCLC cases. Further, FGFR3 was positively expressed in 84.6% of the lung adenocarcinoma (AC) cases and 15.4% of the lung squamous cell carcinoma (SCC) cases. FGFR3 mutations were detected in 2 NSCLC patients (2/72, 2.8%), who both harbored the T450M mutation, a novel mutation in exon 10 of FGFR3. In NSCLC, a high expression of FGFR3 was positively correlated with gender, smoking, histology type, T stage, and the epidermal growth factor receptor (EGFR) mutation (P<0.05). FGFR3 expression was also correlated with better OS and DFS. The multivariate analysis revealed that FGFR3 served as an independent prognostic factor (P=0.024) for the OS of NSCLC patients. Conclusions This study showed that FGFR3 was highly expressed in NSCLC tissues, and the frequency rate for the FGFR3 mutation at T450 M in NSCLC tissues was low. The survival analysis suggested that FGFR3 may be a useful prognostic biomarker in NSCLC.

show abstract

Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review

Cited by 9 publications

References 84 publications

Nanoparticles overcome adaptive immune resistance and enhance immunotherapy via targeting tumor microenvironment in lung cancer

Nanoparticles overcome adaptive immune resistance and enhance immunotherapy via targeting tumor microenvironment in lung cancer

Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer

High expression of FGFR3 predicts a better prognosis for patients with non-small cell lung cancer in a Chinese population

Contact Info

Product

Resources

About